Table 4.

Clinical and Microbiologic Outcomes Among Patients With Baseline Pathogens Demonstrating Phenotypic Resistance Characteristics (Test of Cure, Microbiologic Modified Intent-to-Treat) [9]

	ESBL		Amino-R		CRE		MDR
	Cure, % (n/N)	Eradication, % (n/N)	Cure, % (n/N)	Eradication, % (n/N)	Cure, % (n/N)	Eradication, % (n/N)	Cure, % (n/N)	Eradication, % (n/N)
ZTI-01	93 (52/56)	55 (32/58)	97 (29/30)	67 (20/30)	100 (9/9)	56 (5/9)	92 (34/37)	54 (20/37)
PIP-TAZ	93 (51/55)	47 (27/57)	94 (29/31)	38 (12/32)	85 (11/13)	31 (4/13)	90 (28/31)	36 (12/33)

Using minimum inhibitory concentrations from an accompanying antibiotic panel or agar dilution supplemented with glucose 6-phosphate for fosfomycin, blood or urine isolates were identified to assess patient and microbiologic outcome. The following definitions were used for this assessment—ESBL: ≥2 µg/mL MIC for aztreonam, ceftazidime, or ceftriaxone; CRE: ≥4 µg/mL imipenem or meropenem; Amino-R: gentamicin ≥8 µg/mL or amikacin ≥32 µg/mL; MDR: nonsusceptibility ≥3 classes, using definitions above plus levofloxacin ≥4 µg/mL and trimethoprim/sulfamethoxazole ≥32 g/mL. Patients could have more than 1 isolate from blood and/or urine sources, and all organisms are presented for completeness. Patients with multiple organisms were counted only once per resistance grouping. If the same species was identified from a different source, the isolate was counted once for microbiological outcome.

Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum beta-lactamase; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; ZTI-01, fosfomycin for injection.